References

Publication Details

1.
Turner S, Thomas M, von Ziegenweidt J, Price D. Prescribing trends in asthma: a longitudinal observational study. Arch Dis Child 2008;941:16–22. [PubMed: 18701558]
2.
British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2003;58:1–94. [PMC free article: PMC1766014] [PubMed: 12653493]
3.
Van den Berg NJ, Ossip MS, Hederos CA, Anttila H, Ribeiro BL, Davies PI. Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. Pediatr Pulmonol 2000;30:97–105. [PubMed: 10922131]
4.
Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998;279:1181–6. [PubMed: 9555757]
5.
Verberne AA, Frost C, Duiverman EJ, Grol MH, Kerrebijn KF. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. Am J Respir Crit Care Med 1998;158:213–19. [PubMed: 9655732]
6.
Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219–24. [PubMed: 7913155]
7.
Garrett J, Williams S, Wong C, Holdaway D. Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid. Arch Dis Child 1998;79:12–17. [PMC free article: PMC1717626] [PubMed: 9771245]
8.
Allen D, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteriods on growth. J Allergy Clin Immunol 1994;93:967–76. [PubMed: 8006318]
9.
Russell G. Inhaled corticosteroids and adrenal insufficiency. Arch Dis Child 2002;87:455–6. [PMC free article: PMC1755856] [PubMed: 12456537]
10.
Crowley S. Inhaled glucocorticoids and adrenal function: an update. Paediatr Respir Rev 2003;42:153–61. [PubMed: 12758054]
11.
Committee on Safety of Medicines and Medicines Control Agency. Inhaled corticosteroids and adrenal suppression in children. In Current Problems in Pharmacovigilance, vol. 28, October 2002.
12.
Lemanske RF Jr, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010;362:975–85. [PMC free article: PMC2989902] [PubMed: 20197425]
13.
Juniper E, O'Byrne P, Guyatt G, Ferrie P, King D. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;144:902–7. [PubMed: 10573240]
14.
Friede T, Schmidli H. Blinded sample size reestimation with count data: methods and applications in multiple sclerosis. Stat Med 2010;29:1145–56. [PubMed: 20146203]
15.
The Clinical Practice Research Datalink. URL: www​.cprd.com (accessed 2005).
16.
Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 1971;44:793–7. [PubMed: 4940475]
17.
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585–612. [PMC free article: PMC2025229] [PubMed: 795448]
18.
Schulz K, Altman D, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332. [PMC free article: PMC2844940] [PubMed: 20332509]
19.
Moher D, Hopwell S, Schulz K, Gøtzsche P, Devereaux P, Elbourne D, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869. [PMC free article: PMC2844943] [PubMed: 20332511]
20.
Paediatric Formulary Committee. BNF for Children, 2011–2012. London: BMJ Group, Pharmaceutical Press and RCPCH Publications; 2011.
21.
Manca A, Hawkins N, Sculpher M. Estimating mean QALYs in trial based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487–96. [PubMed: 15497198]
22.
Drummond M, McGuire A. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press; 2001.
23.
Suh D, Manning W, Schondelmeyer S, Hadsall R. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry. Health Services Res 2000;35:529–47. [PMC free article: PMC1089132] [PubMed: 10857475]
24.
Engström A, Jacob J, Lundin D. Sharp drop in prices after the introduction of generic substitution. Solna, Sweden: LFN-Swedish Pharmaceutical Benefits Board; 2006.
25.
Lenney W, Perry S, Price D. Clinical trials and tribulations: the MASCOT study. Thorax 2011;66:457–8. [PubMed: 21398371]
26.
Carroll W, Jones P, Boit P, Clayton S, Cliff I, Lenney W. Childhood evaluation of salmeterol tolerance – a double-blind randomized controlled trial. Pediatr Allergy Immunol 2010;21:366–44. [PubMed: 19725893]
27.
Maspero J, Guerra F, Cuevas F, Gutierrez J, Soto-Ramos M, Anderton S, et al. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: a prospective, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 2008;308:1492–504. [PubMed: 18803991]
28.
de Blic J, Ogorodova L, Klink R, Sidorenko I, Valiulis A, Hofman J, et al. Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. Paediatr Allergy Immunol 2011;208:763–71. [PubMed: 19239660]
29.
Gappa M, Zachgo W, von Berg A, Kamin W, Stern-Strater C, Steinkamp G, et al. Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED). Pediatric Pulmonol 2009;4411:1132–42. [PubMed: 19824054]
30.
Ni Chroinin M, Lasserson T, Greenstone I, Ducharme F. Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2009;3:CD007949. [PMC free article: PMC4167878] [PubMed: 19588447]
31.
Curtis L. Unit costs of health and social care 2010. Canterbury: PPSRU, University of Kent; 2010.
32.
Department of Health (DoH). NHS reference costs 2009–10. London: DoH; 2011. URL: www. dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_123459.